-+ 0.00%
-+ 0.00%
-+ 0.00%

Polaryx Therapeutics Presents PLX-200 Development Update at NCL Conference

PUBT·11/20/2026 13:30:56
Listen to the news
Polaryx Therapeutics Presents PLX-200 Development Update at NCL Conference
  • Polaryx Therapeutics presented its PLX-200 development program at the NCL conference in Quincy, Massachusetts, held November 11-13, 2026.
  • Chief Medical Officer Will Charlton's November 13 presentation included previously published preclinical findings in a CLN3 mouse model.
  • PLX-200 is being evaluated in the SOTERIA Phase 2 basket trial across four rare pediatric lysosomal storage disorders.
  • The first SOTERIA trial site recently activated at Boys Town National Research Hospital in Nebraska.
  • Polaryx also sponsored and attended NTSAD's Imagine & Believe fundraiser on November 12, 2026, in the Boston area.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200830PRIMZONEFULLFEED9881924) on November 20, 2026, and is solely responsible for the information contained therein.